Susquehanna International Group
JSPR icon

Susquehanna International Group’s Jasper Therapeutics JSPR Stock Holding History

Susquehanna International Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,300
Closed -$18.8K – 13643
2025
Q4 		$18.8K Sell
10,300
-15,600
-60% -$31.3K ﹤0.01% 11975
2025
Q3 		$61.6K Sell
25,900
-9,900
-28% -$30K ﹤0.01% 11793
2025
Q2 		$199K Buy
+35,800
New +$176K ﹤0.01% 11214
2025
Q1 		– Sell
-21,700
Closed -$464K – 12998
2024
Q4 		$464K Sell
21,700
-50,400
-70% -$1.05M ﹤0.01% 8856
2024
Q3 		$1.36M Buy
72,100
+39,400
+120% +$784K ﹤0.01% 6136
2024
Q2 		$742K Buy
32,700
+18,800
+135% +$451K ﹤0.01% 7282
2024
Q1 		$408K Buy
+13,900
New +$247K ﹤0.01% 8992
2023
Q2 		– Sell
-1,130
Closed -$20.5K – 12642
2023
Q1 		$20.5K Buy
+1,130
New +$20.9K ﹤0.01% 12044

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Susquehanna International Group's JSPR Position: Q1 2026 in Review

Susquehanna International Group reduced its Jasper Therapeutics (JSPR) stake by 89% in Q1 2026, selling an estimated $130K and leaving 11,149 shares worth $9.77K. The position accounts for ﹤0.01% of the portfolio, ranked #12942.

Susquehanna International Group first reported a position in JSPR in Q4 2022 and has held it in 10 quarters since. The position peaked at $488K in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Susquehanna International Group held 11,149 shares of Jasper Therapeutics worth $9.77K as of Q1 2026.
  • Susquehanna International Group sold 93,638 Jasper Therapeutics shares in Q1 2026, an estimated $130K.
  • Jasper Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12942 holding.
  • Susquehanna International Group first reported a position in Jasper Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Susquehanna International Group's Jasper Therapeutics position peaked at $488K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.